Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

References

• Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, Tabata M, Tanimoto M. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One. 2009;4:e7835. doi:10.1371/journal.pone.0007835. PMID:19915681.
   PubMed Web of Science ®Google Scholar
• Byers LA, Rudin CM. Small cell lung cancer: Where do we go from here? Cancer. 2014;121:664–72.
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43.
   PubMed Web of Science ®Google Scholar
• Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien MER. Treatment options for small cell lung cancer – do we have more choice? Br J Cancer. 2010;102:629–38. doi:10.1038/sj.bjc.6605527.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp K, Baas P, Crinò L, Eberhardt W, Poddubskaya E, Antonia S, Pluzanski A, Vokes E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627–39. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Darnell RB, Posner JB. Paraneoplastic syndromes and the nervous system. N Engl J Med. 2003;3:287–8.
   Google Scholar
• Maddison P, Newsom-Davis J, Mills K, Souhami R. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–8. doi:10.1016/S0140-6736(05)76153-5. PMID:10209997.
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Lang B, Graus F, Van Den Maagdenberg AMJM, Saiz A, De Koning Gans PA, Twijnstra A, Verschuuren JJGM. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol. 2005;164:161–5. doi:10.1016/j.jneuroim.2005.04.001.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8. doi:10.1126/science.aaa1348. PMID:26068851.
   PubMed Web of Science ®Google Scholar
• Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–73. doi:10.1158/0008-5472.CAN-08-4210.
   PubMed Web of Science ®Google Scholar
• Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CHCM, Terada M, Koeffler HP. p53 Mutations in Human Lung Tumors. Cancer Res. 1992;143:1695–8.
   Google Scholar
• Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767–75. doi:10.1002/cncr.24951.
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi. F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensivedisease-small-cell lungcancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24:75–83. doi:10.1093/annonc/mds213.
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34:3740–8. doi:10.1200/JCO.2016.67.6601.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–95. doi:10.1016/S1470-2045(16)30098-5.
   PubMed Web of Science ®Google Scholar
• Ott PA, Elez E, Hiret S, Kim D-W, Morosky A, Saraf S, Piperdi B, Mehnert JM. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol 2017;:JCO. 2017.72.506.
   Google Scholar
• Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, et al. Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. J Thorac Oncol. 2016;11:1511–21. doi:10.1016/j.jtho.2016.05.028.
   PubMed Web of Science ®Google Scholar
• Travis WD. Pathology and Diagnosis of Neuroendocrine Tumors: Lung Neuroendocrine. Thorac Surg Clin. 2014;24:257–66. doi:10.1016/j.thorsurg.2014.04.001.
   PubMed Web of Science ®Google Scholar
• Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 2006;33:270–98. doi:10.1053/j.seminoncol.2006.03.008.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56:715–9. doi:10.1002/ana.20269.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, Thijssen PE, Wirtz PW, Twijnstra A, Smitt PAES, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27:4260–7. doi:10.1200/JCO.2008.20.6169.
   PubMed Web of Science ®Google Scholar
• Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Pnas. 1983;80:7636–40. doi:10.1073/pnas.80.24.7636.
   PubMed Web of Science ®Google Scholar
• Bach JF, Koutouzov S, Van Endert PM. Are there unique autoantigens triggering autoimmune diseases? Immunol Rev. 1998;164:139–55. doi:10.1111/j.1600-065X.1998.tb01216.x.
   PubMed Web of Science ®Google Scholar
• Kai W. Wucherpfennig. Auroimmunity in the Central Nervous System: Mechanisms of Antigen Presentation and Recognition. Clin. Immunol. Immunopathol. 1994;72:293–306.
   PubMedGoogle Scholar
• De Beukelaar JW, Smitt PAS, Hop WC, Kraan J, Hooijkaas H, Verjans GMGM, Gratama JW. Imbalances in circulating lymphocyte subsets in Hu antibody associated paraneoplastic neurological syndromes. Eur J Neurol. 2007;14:1383–91. doi:10.1111/j.1468-1331.2007.01986.x.
   PubMed Web of Science ®Google Scholar
• Albert ML, Darnell JC, Bender a, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998;4:1321–4. doi:10.1038/3315.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer–a quantitative western blot analysis. Ann Neurol. 1990;27:544–52. doi:10.1002/ana.410270515.
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmou J, Reñé R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, Garcia del Muro J, Vadell C, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997;15:2866–72. doi:10.1200/JCO.1997.15.8.2866.
   PubMed Web of Science ®Google Scholar
• Gozzard P, Woodhall M, Chapman C, Nibber A, Waters P, Vincent A, Lang B, Maddison P. Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology. 2015;85:235–9. doi:10.1212/WNL.0000000000001721.
   PubMed Web of Science ®Google Scholar
• Sodeyama N, Ishida K, Jaeckle KA, Zhang L, Azuma A, Yamada M, Mizusawa H, Wada Y. Pattern of epitopic reactivity of the anti-Hu antibody on HuD with and without paraneoplastic syndrome. J Neurol Neurosurg Psychiatry. 1999;66:97–9. doi:10.1136/jnnp.66.1.97.
   PubMed Web of Science ®Google Scholar
• Atakan S, Bayiz H, Sak S, Poyraz A, Vural B, Yildirim AS, Demirag F, Gure AO. Autologous anti-SOX2 antibody responses reflect intensity but not frequency of antigen expression in small cell lung cancer. BMC Clin Pathol. 2014;14:24. doi:10.1186/1472-6890-14-24. PMID:24940116.
   PubMedGoogle Scholar
• Tsou JA, Kazarian M, Ankur Patel M, Janice S., Galler M., Laird-Offringa A, Carpenter CL, J. SL. Low level anti-Hu reactivity: a risk marker for small cell lung cancer? Cancer Detect Prev. 2010;32:292–9. doi:10.1016/j.cdp.2008.06.006.
   Google Scholar
• Hasadsri L, Lee J, Wang BH, Yekkirala L, Wang M. Anti-yo associated paraneoplastic cerebellar degeneration in a man with large cell cancer of the lung. Case Rep Neurol Med. 2013;2013:725936. PMID:24167748.
   PubMedGoogle Scholar
• Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42:1931–7.
   PubMed Web of Science ®Google Scholar
• Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem. 2011;57:168–75. doi:10.1373/clinchem.2010.148205.
   PubMed Web of Science ®Google Scholar
• Gozzard P, Chapman C, Vincent A, Lang B, Maddison P. Novel Humoral Prognostic Markers in Small- Cell Lung Carcinoma : A Prospective Study. 2015;430:1–14.
   Google Scholar
• Berger B, Bischler P, Dersch R, Hottenrott T, Rauer S, Stich O. “Non-classical” paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to “classical” syndromes – More frequent than expected. J Neurol Sci. 2015;352:58–61. doi:10.1016/j.jns.2015.03.027.
   PubMed Web of Science ®Google Scholar
• Verschuuren JJ, Perquin M, ten Velde G, De Baets M, Vriesman PB, Twijnstra A. Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. J Neurol Neurosurg Psychiatry. 1999;67:353–7. doi:10.1136/jnnp.67.3.353.
   PubMed Web of Science ®Google Scholar
• Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res. 1998;4:2819–24.
   PubMed Web of Science ®Google Scholar
• Musunuru K, Darnell RB. Paraneoplastic neurologic disease antigens: RNA-Binding Proteins and Signaling Proteins in Neuronal Degeneration. Annu Rev Neurosci. 2001;24:239–62. doi:10.1146/annurev.neuro.24.1.239.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Maruyama Y, Sugie M, Motizuki H, Kamakura K, Tanaka K. Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci. 2002;201:9–12. doi:10.1016/S0022-510X(02)00157-0.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F, Cheung N-K V., Rosenblum MK, Ho A, Cañete A, Delattre J-Y, Thompson SJ, Posner JB. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer. 1995;75:99–109. doi:10.1002/1097-0142(19950101)75.:1%3c99::AID-CNCR2820750117%3e3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• DeLuca I, Blachère NE, Santomasso B, Darnell RB. Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS One. 2009;4:e5739. doi:10.1371/journal.pone.0005739. PMID:19492067.
   PubMed Web of Science ®Google Scholar
• Posner JB, Dalmau J. Paraneoplastic syndromes. Curr Opin Immunol. 1997;9:723–9. doi:10.1016/S0952-7915(97)80055-6.
   PubMed Web of Science ®Google Scholar
• Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, Carbone DP. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst. 1993;85:2012–8. doi:10.1093/jnci/85.24.2012.
   PubMed Web of Science ®Google Scholar
• Maddison P, Thorpe A, Silcocks P, Robertson JFR, Chapman CJ. Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer. 2010;70:335–9. doi:10.1016/j.lungcan.2010.03.002.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463–9. doi:10.1126/science.aaf1490.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D. Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma. J Immunother. 2012;35:89–97. doi:10.1097/CJI.0b013e31823aa41c.
   PubMed Web of Science ®Google Scholar
• Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJP, van der Burg S, Kapiteijn E, Michielin O, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6:254ra128. doi:10.1126/scitranslmed.3008918. PMID:25232180.
   PubMed Web of Science ®Google Scholar
• Morita M, Fukuhara T, Takahashi H, Maemondo M. Small cell lung cancer and progressive retinopathy. BMJ Case Rep. 2014;2014:2–5. doi:10.1136/bcr-2014-205888.
   Google Scholar
• Hiasa Y, Kunishige M, Mitsui T, Kondo S, Kuriwaka R, Shigekiyo S, Kanematsu T, Satake N, Bando Y, Kondo A, et al. Complicated paraneoplastic neurological syndromes: A report of two patients with small cell or non-small cell lung cancer. Clin Neurol Neurosurg. 2003;106:47–9. doi:10.1016/S0303-8467(03)00059-3.
   PubMed Web of Science ®Google Scholar
• Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409–18. doi:10.1093/brain/awg133.
   PubMed Web of Science ®Google Scholar
• Greenlee JE, Dalmau J, Lyons T, Clawson S, Smith RH, Pirch HR. Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. Ann Neurol. 1999;45:805–9. doi:10.1002/1531-8249(199906)45.:6%3c805::AID-ANA18%3e3.0.CO;2-G.
   PubMed Web of Science ®Google Scholar
• Selby KJ, Warner J, Klempner S, Konstantinopoulos PA, Hecht JL, Ph D. Case Report Anti-Yo Antibody Associated With Occult Fallopian Tube Carcinoma. 2011;:536–8.
   Google Scholar
• Nagashima T, Mizutani Y, Kawahara H, Maguchi S, Terayama Y, Shinohara T, Orba Y, Chuma T, Mano Y, Itoh T, et al. Anti-Hu paraneoplastic syndrome presenting with brainstem-cerebellar symptoms and Lambert–Eaton myasthenic syndrome. Neuropathology. 2003;23:230–8. doi:10.1046/j.1440-1789.2003.00501.x.
   PubMed Web of Science ®Google Scholar
• Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG., Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, et al. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017;19:129–36. doi:10.3233/CBM-160071.
   PubMed Web of Science ®Google Scholar
• Wood O, Woo J, Seumois G, Savelyeva N, McCann KJ, Singh D, Jones T, Peel L, Breen MS, Ward M, et al. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget. 2016;7:56781–97. doi:10.18632/oncotarget.10788.
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–102. doi:10.1038/onc.2009.416.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Galon J, Dieu-Nosjean M-C, Cremer I, Fisson S, Damotte D, Pagès F, Tartour E, Sautès-Fridman C. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol. 2011;344:1–24.
   PubMed Web of Science ®Google Scholar
• Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5:e1240859. doi:10.1080/2162402X.2016.1240859. PMID:28123878.
   PubMed Web of Science ®Google Scholar
• Eerola AK, Soini Y, Pääkkö P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res. 2000;6:1875–81.
   PubMed Web of Science ®Google Scholar
• Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Pnas. 2011;108. doi:10.1073/pnas.1110814108.
   Web of Science ®Google Scholar
• Cañadas I, Taus Á, Villanueva X, Arpí O, Pijuan L, Rodríguez Y, Menéndez S, Mojal S, Rojo F, Albanell J, et al. Angiopoietin-2 is a negative prognostic marker in small cell lung cancer. Lung Cancer. 2015;90:302–6. doi:10.1016/j.lungcan.2015.09.023.
   PubMed Web of Science ®Google Scholar
• Cañadas I, Taus A, González I, Villanueva X, Gimeno J, Pijuan L, Dómine M, Sánchez-Font A, Vollmer I, Menéndez S, et al. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget. 2014;5:5246–56. doi:10.18632/oncotarget.2124.
   PubMed Web of Science ®Google Scholar
• Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, et al. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res. 2014;20:938–50. doi:10.1158/1078-0432.CCR-13-1330.
   PubMed Web of Science ®Google Scholar